Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests (2021 - 2023)

Historic Income from Non-Controlling Interests for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$1.8 million.

  • Cullinan Therapeutics' Income from Non-Controlling Interests fell 47516.34% to -$1.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.9 million, marking a year-over-year increase of 396.24%. This contributed to the annual value of -$192000.0 for FY2024, which is 9009.8% up from last year.
  • As of Q4 2023, Cullinan Therapeutics' Income from Non-Controlling Interests stood at -$1.8 million, which was down 47516.34% from -$179000.0 recorded in Q1 2023.
  • Over the past 5 years, Cullinan Therapeutics' Income from Non-Controlling Interests peaked at $1.5 million during Q1 2021, and registered a low of -$1.8 million during Q4 2023.
  • Its 3-year average for Income from Non-Controlling Interests is -$586200.0, with a median of -$798500.0 in 2021.
  • In the last 5 years, Cullinan Therapeutics' Income from Non-Controlling Interests skyrocketed by 9053.91% in 2022 and then crashed by 47516.34% in 2023.
  • Over the past 3 years, Cullinan Therapeutics' Income from Non-Controlling Interests (Quarter) stood at -$1.7 million in 2021, then skyrocketed by 81.91% to -$306000.0 in 2022, then crashed by 475.16% to -$1.8 million in 2023.
  • Its Income from Non-Controlling Interests was -$1.8 million in Q4 2023, compared to -$179000.0 in Q1 2023 and -$306000.0 in Q4 2022.